CBD for Kids with Epilepsy

August 15, 2020
kid with epilepsy
kid with epilepsy

CBD, Epilepsy and Kids

The FDA has approved the use of CBD for Kids with Epilepsy. The FDA approved Epidiolex, which contains a purified type of the medication compound CBD, for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet disorder in people 2 years of age or older. It has determined that this particular medication is safe and effective for the intended use based on clinical trials and ongoing reporting.


Epilepsy and seizure disorders, especially in children, are debilitating and stunt growth, progress, and can eliminate any qualify of life for the patients as well as the caregivers. That’s why the approval of CBD for Kids with Epilepsy is a huge step forward alleviating symptoms and seizures in this population.


June 25, 2018

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.

CBD is a chemical component of the Cannabis sativa plant, more commonly known as marijuana. However, CBD does not cause intoxication or euphoria (the “high”) that comes from tetrahydrocannabinol (THC).

It is THC (and not CBD) that is the primary psychoactive component of marijuana.

“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies. And, the FDA is committed to this kind of careful scientific research and drug development,” said FDA Commissioner Scott Gottlieb, M.D. “Controlled clinical trials testing the safety and efficacy of a drug, along with careful review through the FDA’s drug approval process, is the most appropriate way to bring marijuana-derived treatments to patients. Because of the adequate and well-controlled clinical studies that supported this approval, prescribers can have confidence in the drug’s uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes. We’ll continue to support rigorous scientific research on the potential medical uses of marijuana-derived products and work with product developers who are interested in bringing patients safe and effective, high quality products. But, at the same time, we are prepared to take action when we see the illegal marketing of CBD-containing products with serious, unproven medical claims. Marketing unapproved products, with uncertain dosages and formulations can keep patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”

Read the full press release on the approval here »